SCHEMBL4604690

SCHEMBL4604690

CCOC(=O)C1=NN(c2ccc(Cl)cc2Cl)C(c2ccc(Cl)s2)C1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.44
KDR P35968 1/20 0.44
GABRA2 P47869 7/20 0.42
GABRB2 P47870 7/20 0.42
CNR1 P21554 3/20 0.42
CNR2 P34972 3/20 0.42
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
P2RY12 Q9H244 1/20 0.41
KDM4E B2RXH2 3/20 0.39
MAPT P10636 3/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MEN1 O00255 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
SLC5A1 P13866 1/20 0.39
SLC5A2 P31639 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4605564 0.90 GABRA2 (0.45) EGFRKDRGABRA2GABRB2CNR1
SCHEMBL4606740 0.89 CNR1 (0.46) EGFRKDRGABRA2GABRB2CNR1
SCHEMBL14621419 0.89 CNR1 (0.46) EGFRKDRGABRA2GABRB2CNR1
SCHEMBL4604310 0.85 GABRA2 (0.46) EGFRKDRGABRA2GABRB2CNR1
SCHEMBL8466368 0.85 CNR1 (0.57) EGFRKDRGABRA2GABRB2CNR1
SCHEMBL2020050 0.85 CNR1 (0.57) EGFRKDRGABRA2GABRB2CNR1
SCHEMBL31588918 0.85 CNR1 (0.57) EGFRKDRGABRA2GABRB2CNR1
SCHEMBL4604890 0.84 CNR1 (0.47) GABRA2GABRB2CNR1CNR2LMNA
SCHEMBL4607493 0.84 CNR1 (0.47) CNR1CNR2LMNA
SCHEMBL31429978 0.83 ALDH1A1 (0.57) EGFRKDRGABRA2GABRB2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP claimed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP claimed
EP-1743894-A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP claimed
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1743894-A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP disclosed
EP-1743894-A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP disclosed